AU2017219834B2 - BYL719 (Alpelisib) for use in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS - CLOVES syndrome) - Google Patents

BYL719 (Alpelisib) for use in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS - CLOVES syndrome) Download PDF

Info

Publication number
AU2017219834B2
AU2017219834B2 AU2017219834A AU2017219834A AU2017219834B2 AU 2017219834 B2 AU2017219834 B2 AU 2017219834B2 AU 2017219834 A AU2017219834 A AU 2017219834A AU 2017219834 A AU2017219834 A AU 2017219834A AU 2017219834 B2 AU2017219834 B2 AU 2017219834B2
Authority
AU
Australia
Prior art keywords
pros
byl719
pik3ca
treatment
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017219834A
Other languages
English (en)
Other versions
AU2017219834A1 (en
Inventor
Guillaume CANAUD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Cite
Original Assignee
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Cite filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU2017219834A1 publication Critical patent/AU2017219834A1/en
Assigned to CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSERM (Institut National de la Santé et de la Recherche Médicale), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), Universite De Paris reassignment CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) Request for Assignment Assignors: ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSERM (Institut National de la Santé et de la Recherche Médicale), UNIVERSITÉ PARIS DESCARTES
Assigned to CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSERM (Institut National de la Santé et de la Recherche Médicale), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS CITÉ reassignment CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) Amend patent request/document other than specification (104) Assignors: ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSERM (Institut National de la Santé et de la Recherche Médicale), Universite De Paris
Application granted granted Critical
Publication of AU2017219834B2 publication Critical patent/AU2017219834B2/en
Priority to AU2022235569A priority Critical patent/AU2022235569B2/en
Priority to AU2024278598A priority patent/AU2024278598A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Spectrometry And Color Measurement (AREA)
AU2017219834A 2016-02-19 2017-02-17 BYL719 (Alpelisib) for use in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS - CLOVES syndrome) Active AU2017219834B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022235569A AU2022235569B2 (en) 2016-02-19 2022-09-21 BYL719 (Alpelisib) for use in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS - CLOVES syndrome)
AU2024278598A AU2024278598A1 (en) 2016-02-19 2024-12-19 BYL719 (Alpelisib) for use in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS - CLOVES syndrome)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305193.1 2016-02-19
EP16305193 2016-02-19
PCT/EP2017/053587 WO2017140828A1 (en) 2016-02-19 2017-02-17 Byl719 (alpelisib) for use in the treatment of pik3ca-related overgrowth spectrum (pros - cloves syndrome)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022235569A Division AU2022235569B2 (en) 2016-02-19 2022-09-21 BYL719 (Alpelisib) for use in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS - CLOVES syndrome)

Publications (2)

Publication Number Publication Date
AU2017219834A1 AU2017219834A1 (en) 2018-08-23
AU2017219834B2 true AU2017219834B2 (en) 2022-06-30

Family

ID=55409795

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017219834A Active AU2017219834B2 (en) 2016-02-19 2017-02-17 BYL719 (Alpelisib) for use in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS - CLOVES syndrome)
AU2022235569A Active AU2022235569B2 (en) 2016-02-19 2022-09-21 BYL719 (Alpelisib) for use in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS - CLOVES syndrome)
AU2024278598A Pending AU2024278598A1 (en) 2016-02-19 2024-12-19 BYL719 (Alpelisib) for use in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS - CLOVES syndrome)

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022235569A Active AU2022235569B2 (en) 2016-02-19 2022-09-21 BYL719 (Alpelisib) for use in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS - CLOVES syndrome)
AU2024278598A Pending AU2024278598A1 (en) 2016-02-19 2024-12-19 BYL719 (Alpelisib) for use in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS - CLOVES syndrome)

Country Status (8)

Country Link
US (4) US11433059B2 (enExample)
EP (1) EP3416642A1 (enExample)
JP (3) JP7051693B2 (enExample)
KR (1) KR20180115297A (enExample)
CN (3) CN109562103A (enExample)
AU (3) AU2017219834B2 (enExample)
CA (1) CA3013845C (enExample)
WO (1) WO2017140828A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296390A (en) * 2015-05-15 2022-11-01 Memorial Sloan Kettering Cancer Center Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations
CN109562103A (zh) 2016-02-19 2019-04-02 国家医疗保健研究所 用于治疗pik3ca相关过度生长综合征群的方法
KR20210124310A (ko) 2019-02-06 2021-10-14 벤테라, 인코포레이티드 국소 포스포이노시티드 3-키나제 억제제
WO2025045915A1 (en) * 2023-08-29 2025-03-06 Institut National de la Santé et de la Recherche Médicale Methods for inducing muscle hypertrophy
WO2025045129A1 (zh) * 2023-08-30 2025-03-06 广州嘉越医药科技有限公司 化合物用于治疗pros谱系疾病的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187157A1 (en) * 2015-05-15 2016-11-24 Memorial Sloan-Kettering Cancer Center Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027013A2 (en) * 2006-08-29 2008-03-06 National Cancer Centre Combination of mtor antagonist and angiogenesis inhibitor for the treatment of cancer
AR082418A1 (es) * 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
UA118846C2 (uk) * 2013-03-21 2019-03-25 Новартіс Аг Комбінована терапія
CN109562103A (zh) 2016-02-19 2019-04-02 国家医疗保健研究所 用于治疗pik3ca相关过度生长综合征群的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187157A1 (en) * 2015-05-15 2016-11-24 Memorial Sloan-Kettering Cancer Center Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIMAYE NISHA ET AL, "Somatic ActivatingPIK3CAMutations Cause Venous Malformation", AMERICAN JOURNAL OF HUMAN GENETICS, (2015-12-03), vol. 97, no. 6, doi:10.1016/J.AJHG.2015.11.011, ISSN 0002-9297, pages 914 - 921 *

Also Published As

Publication number Publication date
AU2022235569A1 (en) 2022-10-13
AU2024278598A1 (en) 2025-01-16
US20250295645A1 (en) 2025-09-25
WO2017140828A1 (en) 2017-08-24
AU2017219834A1 (en) 2018-08-23
KR20180115297A (ko) 2018-10-22
JP7051693B2 (ja) 2022-04-11
EP3416642A1 (en) 2018-12-26
CA3013845C (en) 2024-09-17
AU2022235569B2 (en) 2024-10-10
US20250339417A1 (en) 2025-11-06
CN118477076A (zh) 2024-08-13
US20200215044A1 (en) 2020-07-09
US11433059B2 (en) 2022-09-06
JP2019505549A (ja) 2019-02-28
US20220323428A1 (en) 2022-10-13
CN109562103A (zh) 2019-04-02
US12427141B2 (en) 2025-09-30
JP2024125429A (ja) 2024-09-18
CN118477075A (zh) 2024-08-13
CA3013845A1 (en) 2017-08-24
JP2022058800A (ja) 2022-04-12

Similar Documents

Publication Publication Date Title
AU2022235569B2 (en) BYL719 (Alpelisib) for use in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS - CLOVES syndrome)
Luo et al. Perfect match: mTOR inhibitors and tuberous sclerosis complex
ES2887042T3 (es) Moduladores del receptor S1P para el tratamiento de la esclerosis múltiple
EP3498278B1 (en) Compounds for treatment of diseases related to dux4 expression
CN108289870A (zh) 治疗特定患者群体的神经变性病症的方法
Cao et al. Ruxolitinib improves the inflammatory microenvironment, restores glutamate homeostasis, and promotes functional recovery after spinal cord injury
Quinn et al. Effects of dantrolene therapy on disease phenotype in dystrophin deficient mdx mice
Hayes et al. Preserved Left Ventricular Function despite Myocardial Fibrosis and Myopathy in the Dystrophin‐Deficient D2. B10‐Dmdmdx/J Mouse
US20210283083A1 (en) Use of tyrosine hydroxylase inhibitors for the treatment of aortic aneurysm
EP3856340A1 (en) Combined sirolimus and nintedanib therapy for vascular lesions and hereditary hemorrhagic telangiectasia
JP7536987B2 (ja) 脈管奇形用医薬組成物及び脈管奇形の治療方法
TW202519221A (zh) Ｗｅｅ１抑制劑及ｐｋｍｙｔ１抑制劑之組合
Górska Diffuse alveolar hemorrhage in a chronically hemodialyzed patient with progressive necrotic skin lesions as a manifestation of calciphylaxis
Bonnard et al. Macrophage Neutrophil Gelatinase-Associated Lipocalin Has a Critical Role in Aldosterone-Induced Renal Fibrosis via the CCL5-IL4 Pathway: PO2129
WO2025125788A1 (en) Sabizabulin for use in the treatment of polycystic kidney disease
Eser et al. Intracerebral Hematoma Complicated With Brain Abscess in an Infant—Case Report—
Brackhan Investigation of brain inflammation as a nuclear imaging biomarker of epileptogenesis and a treatment target for epilepsy prevention
Miao et al. Apelin-13 ameliorates hypoxic-ischemic brain damage and improves neurological function in neonatal rats by attenuating neuroinflammation via AMPK activation
HK1214758B (en) S1p receptor modulators for treating multiple sclerosis

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: UNIVERSITE DE PARIS

Free format text: FORMER APPLICANT(S): INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE PARIS DESCARTES; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Free format text: FORMER APPLICANT(S): INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE PARIS DESCARTES; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

Free format text: FORMER APPLICANT(S): INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE PARIS DESCARTES; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)

Owner name: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)

Free format text: FORMER APPLICANT(S): INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE PARIS DESCARTES; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)

HB Alteration of name in register

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Free format text: FORMER NAME(S): UNIVERSITE DE PARIS; ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

Free format text: FORMER NAME(S): UNIVERSITE DE PARIS; ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Owner name: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)

Free format text: FORMER NAME(S): UNIVERSITE DE PARIS; ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Owner name: UNIVERSITE PARIS CITE

Free format text: FORMER NAME(S): UNIVERSITE DE PARIS; ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

FGA Letters patent sealed or granted (standard patent)